Press / media

Fraunhofer IZI is part of the EU consortium EASYGEN. Coordinated by Fresenius, 18 industrial and academic partners are working together to develop an integrated and automated manufacturing platform for the decentralized production of CAR-T cell therapeutics. In this context, Fraunhofer IZI contributes its expertise in the development and manufacturing of CAR-T cell therapies as well as various other cell-based therapeutics. EASYGEN is funded by the EU under the Innovative Health Initiative Joint Undertaking (IHI JU).

The first patient was treated with a new CAR-T cell therapy as part of the LION-1 phase I clinical trial at the University Hospital of Würzburg.

Leipzig, April 29, 2025: The Fraunhofer Institute for Cell Therapy and Immunology (IZI) marked its 20th anniversary in Leipzig, celebrating the milestone with over 400 guests and employees. Invited had been representatives from academia, industry, and politics The event included congratulatory messages from Saxony’s Minister President Michael Kretschmer and Leipzig’s Lord Mayor Burkhard Jung, among others.

Together with Primogene GmbH, a Leipzig-based biotech company, the Fraunhofer Institute for Cell Therapy and Immunology IZI is investigating whether breast milk could be significant in the prevention of serious infections beyond infancy.